Healthcare

● Monopar Therapeutics shares have fallen sharply, most recently closing at $110.88, down 10.47%, only a fraction below its 52-week high of about $124.82, after a run that lifted marketCapitalizationpast $830 million.

● EyePoint shares have fallen sharply, most recently closing at $5.40, down 14.29%, after Duravyu missed its primary best-corrected visual acuity endpoint against Eylea at weeks 52 and 56 in a pivotal Phase 3 wet AMD trial.

● Greenwich LifeSciences shares have fallen sharply, most recently closing at $15.31, down 11.71%, without a confirmed clinical, regulatory, or financing catalyst identified in available reporting.

● Eikon Therapeutics shares have fallen sharply, most recently closing at $10.75, down 10.49%, well below its $18.00 IPO price, when the company raised about $381 million.

● Evommune shares have fallen sharply, most recently closing at $13.57, down 9.63%, extending pressure since EVO756 missed its primary endpoint in a chronic spontaneous urticaria trial, showing no statistically significant change in Urticaria Activity Score at any dose.

● Editas Medicine shares have fallen sharply, most recently closing at $2.94, down 9.54%, with no confirmed company-specific catalyst identified, consistent with sector-wide pressure on early-stage gene-editing biotech.

● Edesa Biotech shares have fallen sharply, most recently closing at $4.76, down 17.22%, extending weakness tied to a $25.0 million public offering priced at a combined $5.50 per unit.